|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma:A cohort study显示文摘AIM:To prospectively evaluate the short and long term clinical impact of selective transarterial chemoembolization (TACE) on liver function in patients with hepatocellular carcinoma (HCC).To assess side effects in relation to treatments.To analyze the overall survival and HCC progression free survival probability. METHODS:One hundred and seventeen cirrhotic patients with HCC were enrolled.Baseline liver function included Child-Pugh score and serum levels of alanineaminotransferase (ALT),prothrombin time(PT)and bilirubin.According to Cancer Liver Italian Program (CLIP) and Barcelona Clinic Liver Cancer (BCLC) staging systems,71 patients were eligible for TACE; 32 had previously received treatment for HCC.No significant differences in liver function were observed between previously treated and not treated patients. TACE was performed by selective catheterization of the arteries nourishing the lesions.While hospitalized, patient sunder went clinical,hematologicand ultrasonographic assessments.One month after TACE a CT scan was performed to assess tumor response. A second TACE was performed'on demand'.Liver function tests were checked in all patients every four months.RESULTS:After first TACE,the mean Child-Pugh score increased from a mean baseline 5.62±1.12 to 6.11±1.57 at discharge time (P<0.0001),decreasing after four months to 5.81±0.73 (not significant).ALT,PT and bilirubin significantly (P<0.0001)increased 24 h after TACE and progressively decreased until discharge. After the second TACE,variations in Child-Pugh score,ALT,PT and bilirubin were comparable to that described after the first TACE.No major complications were observed.The mean follow-up was 14.7±6.3 mo (median:16 mo).Only one patient died.No other patient experienced important long term worsening of clinical status.The overall survival probability at twenty-four months was 98.18%with a correspondent HCC progression free survival probability of 69%. CONCLUSION:Selectiv TAC Emayproduce significant,but transitory increases in ALT values, with no major impact on liver function and Child-Pugh score.Preservation of liver function is achievable also in patients previously treated with other therapeutic modalities and in patients undergoing multiple TACE cycles.Liver function can remain stable in the long-term, with optimal medium term survival.This result can be achieved through rigorous patient selection on the basis of tumour characteristics and clinical conditions. | Rodolfo Sacco Marco Bertini Pasquale Petruzzi Michele Bertoni Irene Bargellini Giampaolo Bresci Graziana Federici Luigi Gambardella Salvatore Metrangolo Giuseppe Parisi Antonio Romano Antonio Scaramuzzino Emanuele Tumino Alessandro Silvestri Emanuele Altomare Claudio Vignali Alfonso Capria | 2009 | World Journal of Gastroenterology2009，15，15： | 7 |
| 2 | Occult and obscure gastrointestinal bleeding:Causes and diagnostic approach in 2009显示文摘Gastrointestinal bleeding can be obscure or occult(OGIB),the causes and diagnostic approach will be discussed in this editorial.The evaluation of OGIB consists on a judicious search of the cause of bleeding,which should be guided by the clinical history and physical findings.The standard approach to patients with OGIB is to directly evaluate the gastrointestinal tract by endoscopy,abdominal computed tomography,angiography,radionuclide scanning,capsule endoscopy.The source of OGIB can be identified in 85%-90%,no bleeding sites will be found in about 5%-10% of cases.Even if the bleedings originating from the small bowel are not frequent in clinical practice(7.6% of all digestive haemorrhages,in our casuistry),they are notoriously difficult to diagnose.In spite of progress,however,a number of OGIB still remain problematic to deal with at present in the clinical context due to both the difficulty in exactly identifying the site and nature of the underlying source and the difficulty in applying affective and durable diagnostic approaches so no single technique has emerged as the most efficient way to evaluate OGIB. | Giampaolo Bresci | 2009 | World Journal of Gastrointestinal Endoscopy2009，1，1： | 5 |
| 3 | Treatment of active steroid-refractory inflammatory bowel diseases with granulocytapheresis: Our experience with a prospective study显示文摘瞄准:与活跃的类固醇倔强的煽动性的肠疾病(IBD ) 在 14 个病人与 granulocytapheresis (GCAP ) 的使用报导我们的经验以便在完成宽恕并且维持一个长持续没有症状的时期评估它的功效。方法:疾病的活动被临床的活动索引(蔡) 和内视镜的索引(EI ) 在 ulcerative (UC ) 评估,当时由 Crohn 在 Crohn 的疾病(CD ) 的疾病活动索引(CDAI ) 。病人用 Adacolumn 系统被对待,有选择地绑在 granulocytes 和单核白血球的吸附列。GCAP 的一个会议 / 星期为 5 wk 被执行。类固醇在词首字母的脱落期间被停止。结果:所有病人完成了不显示出复杂并发症的五星期的功课。在最后会议的结束, 93% 病人显示出为 6 瞬间坚持了的疾病的临床的宽恕。在治疗的结束以后的九个月, 60% 案例维持了宽恕,当 23% 病人仍然在在 12 瞬间以后的临床的宽恕时。结论:就算我们有类固醇倔强的 IBD 的病人的数字不大,我们能断言 GCAP 很好被容忍并且有效特别在在治疗以后的开始的六个月内,在盒子的一个重要百分比。持续反应的率在 12 瞬间以后在 6 瞬间以后并且显著地稍微落下,然而,严重副作用的缺席能是为进一步评估治疗的新时间表的刺激。 | Bresci Giampaolo Parisi Giuseppe Bertoni Michele Mazzoni Alessandro Scatena Fabrizio Capria Alfonso | 2006 | World Journal of Gastroenterology2006，12，14： | 5 |
| 4 | Transarterial radioembolization for hepatocellular carcinoma:An update and perspectives显示文摘In the last decade trans-arterial radioembolization has given promising results in the treatment of patients with intermediate or advanced stage hepatocellular carcinoma(HCC),both in terms of disease control and tolerability profile.This technique consists of the selective intra-arterial administration of microspheres loaded with a radioactive compound(usually Yttrium90),and exerts its therapeutic effect through the radiation carried by these microspheres.A careful and meticulous selection of patients is crucial before performing the radioembolization to correctly perform the procedure and reduce the incidence of complications.Radioembolization is a technically complex and expensive technique,which has only recently entered clinical practice and is supported by scant results from phase Ⅲ clinical trials.Nevertheless,it may represent a valid alternative to transarterial chemoembolization(TACE) in the treatment of intermediate-stage HCC patients,as shown by a comparative retrospective assessment that reported a longer time to progression,but not of overall survival,and a more favorable safety profile for radioembolization.In addition,this treatment has reported a higher percentage of tumor shrinkage,if compared to TACE,for pre-transplant downsizing and it represents a promising therapeutic option in patients with large extent of disease and insufficient residual liver volume who are not immediately eligible for surgery.Radioembolization might also be a suitable companion to sorafenib in advanced HCC or it can be used as a potential alternative to this treatment in patients who are not responding or do not tolerate sorafenib. | Rodolfo Sacco Valeria Mismas Sara Marceglia Antonio Romano Luca Giacomelli Marco Bertini Graziana Federici Salvatore Metrangolo Giuseppe Parisi Emanuele Tumino Giampaolo Bresci Ambra Corti Manuel Tredici Michele Piccinno Luigi Giorgi Carlo Bartolozzi Irene Bargellini | 2015 | World Journal of Gastroenterology2015，21，21： | 4 |
| 5 | Clinical epidemiology of chronic viral hepatitis B:A Tuscany real-world large-scale cohort study显示文摘AIM To build a regional database of chronic patients to define the clinical epidemiology of hepatitis B virus(HBV)-infected patients in the Tuscan public health care system.METHODS This study used a cross-sectional cohort design. We evaluated chronic viral hepatitis patients with HBV referred to the outpatient services of 16 hospital units. Information in the case report forms included main demographic data, blood chemistry data, viral hepatitis markers, instrumental evaluations, and eligibility for treatment or ongoing therapy and liver transplantation. RESULTS Of 4015 chronic viral hepatitis patients, 1096(27.3%) were HBV infected. The case report form was correctly completed for only 833 patients(64% males, 36% females; mean age 50.1 ± 15.4). Of these HBV-infected patients, 73% were Caucasian, 21% Asian, 4% Central African, 1% North African and 1% American. Stratifying patients by age and nationality, we found that 21.7% of HBV-infected patients were aged < 34 years(only 2.8% were Italian). The most represented routes of transmission were nosocomial/dental procedures(23%), mother-to-child(17%) and sexual transmission(12%). The most represented HBV genotypes were D(72%) and A(14%). Of the patients, 24.7% of patients were HBe Ag positive, and 75.3% were HBe Ag negative. Of the HBV patients 7% were anti-HDV positive. In the whole cohort, 26.9% were cirrhotic(35.8% aged < 45 years), and 47% were eligible for or currently undergoing treatment, of whom 41.9 % were cirrhotic. CONCLUSION Only 27.3% of chronic viral hepatitis patients were HBV infected. Our results provide evidence of HBV infection in people aged < 34 years, especially in the foreign population not protected by vaccination. In our cohort of patients, liver cirrhosis was also found in young adults. | Cristina Stasi Caterina Silvestri Roberto Berni Maurizia Rossana Brunetto Anna Linda Zignego Cristina Orsini Stefano Milani Liana Ricciardi Andrea De Luca Pierluigi Blanc Cesira Nencioni Donatella Aquilini Alessandro Bartoloni Giampaolo Bresci Santino Marchi Franco Filipponi Piero Colombatto Paolo Forte Andrea Galli Sauro Luchi Silvia Chigiotti Alessandro Nerli Giampaolo Corti Rodolfo Sacco Paola Carrai Angelo Ricchiuti Massimo Giusti Paolo Almi Andrea Cozzi Silvia Carloppi Giacomo Laffi Fabio Voller Francesco Cipriani | 2018 | World Journal of Hepatology2018，10，5： | 3 |
| 6 | Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: A prospective cohort study显示文摘 | Irene Bargellini Rodolfo Sacco Elena Bozzi Marco Bertini Barbara Ginanni Antonio Romano Antonio Cicorelli Emanuele Tumino Graziana Federici Roberto Cioni Salvatore Metrangolo Michele Bertoni Giampaolo Bresci Giuseppe Parisi Emanuele Altomare Alfonso Capri | 2011 | European Journal of Radiology2011，，6： | 2 |
| 7 | Assessment of clinical and radiological response to sorafenib in hepatocellular carcinoma patients显示文摘Sorafenib is an effective anti-angiogenic treatment forhepatocellular carcinoma(HCC). The assessment of tumor progression in patients treated with sorafenib is crucial to help identify potentially-resistant patients,avoiding unnecessary toxicities. Traditional methods to assess tumor progression are based on variations in tumor size and provide unreliable results in patients treated with sorafenib. New methods to assess tumor progression such as the modified Response Evaluation Criteria in Solid Tumors or European Association for the Study of Liver criteria are based on imaging to measure the vascularization and tumor volume(viable or necrotic). These however fail especially when the tumor response results in irregular development of necrotic tissue. Newer assessment techniques focus on the evaluation of tumor volume,density or perfusion. Perfusion computed tomography and Dynamic ContrastEnhanced-UltraS ound can measure the vascularization of HCC lesions and help predict tumor response to antiangiogenic therapies. Mean Transit Time is a possible predictive biomarker to measure tumor response. Volumetric techniques are reliable,reproducible and time-efficient and can help measure minimal changes in viable tumor or necrotic tissue,allowing the prompt identification of non-responders. Volume ratio may be a reproducible biomarker for tumor response. Larger trials are needed to confirm the use of these techniques in the prediction of response to sorafenib. | Rodolfo Sacco Valeria Mismas Antonio Romano Marco Bertini Michele Bertoni Graziana Federici Salvatore Metrangolo Giuseppe Parisi Emanuele Tumino Giampaolo Bresci Luca Giacomelli Sara Marceglia Irene Bargellini | 2015 | World Journal of Hepatology2015，7，1： | 2 |
| 8 | Pulmonary or otolaryngologic extraesophageal manifestations in patients with gastroesophageal reflux disease显示文摘The extraesophageal manifestations of gastroesophageal reflux disease that are similar to a heart attack or gastric diseases are well known, while those categorized as pulmonary or otolaryngological are less known and less studied. In this article, we introduce this less known aspect of gastroesophageal reflux. | Giampaolo Bresci Rodolfo Sacco | 2010 | World Journal of Gastrointestinal Endoscopy2010，2，2： | 2 |
| 9 | The role of video capsule endoscopy for evaluating obscure gastrointestinal bleeding: usefulness of early use显示文摘 | Giampaolo Bresci Giuseppe Parisi Michele Bertoni Emanuele Tumino Alfonso Capria | 2005 | Journal of Gastroenterology2005，，3： | 2 |
| 10 | Order in Polymers with Biphenylyl Residues in the Side-groups显示文摘 | Frosini V Lupinacci D | 1980 | Makromol Chem Rapid Commun1980，1，3： | 1 |
| 11 | Catalytic upgrading of pyrolytic oils over HZSM25 zeolite: behaviour of the catalyst when used in repeated upgrading regenerating cacles显示文摘 | Vitolo S Bresci B Seggiani M | 2001 | Fuel2001，，80： | 1 |
| 12 | Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial显示文摘 | VEMIA P ANNESE V BRESCI G | 2003 | Eur J Clin Invest2003，33，3： | 1 |
| 13 | The role of video capsule endoscopy for evaluating obscure gastrointestinal bleeding: usefulness of early use显示文摘 | Giampaolo Bresci Giuseppe Parisi Michele Bertoni Emanuele Tumino Alfonso Capria | 2005 | Journal of Gastroenterology2005，，3： | 1 |
| 14 | Catalytic upgrading of pyrolytic oils over HZSM-5 zeolite: behaviour of the catalyst when used in repeated upgrading regenerating cycles 显示文摘 | Vitolo S Bresci B | 2001 | Fuel2001，80，： | 1 |
| 15 | Topical butyrate improves efficacy of 52ASA in refractory distal ulcerative colitis: results of a multicentre trial显示文摘 | Vemia P Annese V Bresci G | 2003 | Eur J Clin Invest2003，33，3： | 1 |
| 16 | Portal hypertension:the management of esophageal/ gastric varices,portal hypertensive gastropathy or hyperten- sive colopathy显示文摘 | Bresci G | 2016 | Therapy2016，4，4： | 1 |
| 17 | Catalytic upgrading of pyrolytic oils over HZSM-5 zeolite:behavior of the catalyst when used in repeated upgrading-regeneration cycles显示文摘 | Vitolo S Bresci B Seggiani M | 2001 | Fuel2001，80，： | 1 |
| 18 | Early fresh-frozen plasma transfusion decreases the risk of retinopa- thy of prematurity 显示文摘 | Dani C Poggi C Bresci C Corsini I Frosini S Ih'atesi S | 2013 | Transfusion2013，54，4： | 1 |
| 19 | Management of hepatic encephalopathy with oral zinc supplementation : a long-term treatment 显示文摘 | Bresci G Parisi G Banti S | 1993 | Eur J Med1993，2，7： | 1 |
| 20 | Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis:results of a multicentre trial显示文摘 | Annese V Bresci G | 2003 | Eur J Clin Invest2003，33，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员